The company's non-invasive eye scanner uses hyperspectral Imagery and machine learning to detect Alzheimer's disease biomarkers in the eye, allowing for early detection of the disease years before symptoms occur. This enables clinicians to intervene with emerging therapeutics early, when there's a chance of actually impacting the disease. The test is simple to administer and inexpensive, making it an accessible tool for healthcare providers to detect Alzheimer's disease early.